Document is current

Article History

Received: 14 July 2023

Revised: 24 October 2023

Accepted: 6 November 2023

First Online: 23 November 2023

Competing interests

: HJS received honoraria and travel grants for lectures and advisory board meetings from Roche, Merk, Servier, AstraZeneca, Novartis, Sanofi, BMS. KB received honoraria for lectures and advisory board meetings Amgen, Roche, Sanofi-Aventis, Servier, Merck Serono. BH received personal fees and/or grants from Amgen, Bayer, Janssen, Lilly, Merck, Roche, Sanofi and Teva. AV received honoraria for lectures and advisory board meetings from Roche, Bayer, Sanofi, BMS, Lilly, Novartis, EISAI, AstraZeneca, Merck, Incyte, Medac, Ipsen, Servier, PierreFabre, MSD, BTG, Janssen and research funding from Servier. CB received institutional research grants and honoraria for lectures and advisory board meetings from Merck Darmstadt, BMS, Roche, Sanofi, Bayer Healthcare, AstraZeneca, Hexal, MSD, BioNTech, ODC and AOK Healthcare. AS received institutional research grants from Merck, BMS, Roche, Sanofi, Servier, German Cancer Aid and Federal Joint Committee and honoraria for lectures and advisory board meetings by Merck, Roche, Amgen, Lilly, Sanofi-Aventis, Servier, Bayer, BMS, MSD and Sirtex. The remaining authors declare no competing interests.

: The study was conducted in accordance with the principles of good clinical practice and the Declaration of Helsinki. The study protocol was approved by the local ethics committees and was subject to authorisation by the competent authority. All participants provided written informed consent.

: Not applicable.